Cardiovascular problems in dialysis patients - focus on correcting hyperphosphatemia
Mineral-bone disorder in chronic kidney disease (CKD-MBD) is one of the most important factor determining prognosis in dialysis patients. CKD-MBD syndrome occurs at the CKD stage 2 and reaches its maximum in patients with end-stage renal disease. Currently, hyperphosphatemia plays a central role in...
Main Authors: | A. M. Essaian, A. R. Rind |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2020-10-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/5813 |
Similar Items
-
Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients
by: Rameez Imtiaz, et al.
Published: (2017-02-01) -
Hyperphosphatemia is a complication of reduced kidney functions and limit for renoprotection
by: S.V. Kushnirenko
Published: (2020-02-01) -
Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease
by: Cernaro V, et al.
Published: (2020-09-01) -
Phosphate binders in chronic kidney disease: The positions of sevelamer
by: V V Fomin, et al.
Published: (2013-06-01) -
How to assess the efficacy of phosphate binders
by: Francisco Caravaca, et al.
Published: (2017-05-01)